T1	Participants 12 43	Japanese breast cancer patients
T2	Participants 177 327	subgroup of postmenopausal, estrogen receptor-positive Japanese breast cancer patients from the Pre-Operative "Arimidex" Compared with Tamoxifen trial
T3	Participants 450 523	Patients with large, potentially operable, locally-advanced breast cancer
